Skip to ContentSkip to Navigation
How to find us H.A.M. Kooistra


Beware overestimation of thrombosis in ICU: Mortality is not the only competing risk!

More precise dosing of acenocoumarol for better control in patients aged above 80 years, a randomised controlled pilot study

Quality of life after switching from well-controlled vitamin K antagonist to direct oral anticoagulant: Little to GAInN

CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL

Choosing between continuing vitamin K antagonists (VKA) or switching to a direct oral anticoagulant in currently well-controlled patients on VKA for atrial fibrillation: a randomised controlled trial (GAInN)

CD47 Expression Defines the Efficacy of Rituximab in Non-Germinal Center B-Cell (non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)

Risk factors for venous thromboembolism in patients treated for differentiated thyroid carcinoma

Determinants of effective, safe and convenient vitamin K antagonist use

Impact of Vitamin K Antagonists on Quality of Life in a Prospective Cohort of 807 Atrial Fibrillation Patients

Risk of Bleeding and Thrombosis in Patients 70 Years or Older Using Vitamin K Antagonists

Read more